



DAC/#

#13

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/879,710	
	Filing Date	June 12, 2001	
	First Named Inventor	BATES, James N.	
	Art Unit	1654 ✓	
	Examiner Name	MELLER, Michael V.	
Total Number of Pages in This Submission	15	Attorney Docket Number	P04852US0

RECEIVED
NOV 03 2003
TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks Petition for Withdrawal of Abandonment (in duplicate) Copy of Auto-Reply Facsimile Transmission dated 4/14/03 Copy of the complete response previously filed (7 pages)	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Edmund J. Sease, Reg. No. 24,741 McKee, Voorhees & Sease, P.L.C.
Signature	
Date	

RECEIVED
OCT 29 2003
OFFICE OF PETITIONS

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Edmund J. Sease, Reg. No. 24,741
Signature	
Date	OCT 24, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Bates et al.
SERIAL NO : 09/879,710
FILED : June 12, 2001
TITLE : S-Methylcysteine, S-Ethylcysteine, and Related S-Alkylthiols as Antagonists to the Effects of S-Nitrosothiols and Nitric Oxide

Grp./A.U. : 1654
Examiner : MELLER, Michael V.
Conf. No. : 3776
Docket No. : P04852US0

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR WITHDRAWAL OF ABANDONMENT

PETITION

1. Applicant petitions that the abandonment set forth in the notice mailed by the Office on October 2, 2003 be withdrawn.

SUBMISSION

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

2. Submitted herewith is:

☐ A copy of the page of the response mailed on _____
showing a Certificate of Mailing executed on _____.

☒ A copy of the Auto-Reply Fax Transmission sent on April 14, 2003.

10/29/2003 AWONDAF1 00000068 260084 09879710

01 FC:1460 130.00 DA

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☒ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Mail Stop Petition, Alexandria, VA 22313-1450.

Date: Oct 24, 2003

FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office, Art Unit 1651 at Fax No. (703) 872-_____.

Edmund J. Sease

- ☒ A copy of the complete response previously filed.
- ☐ A copy of the cancelled check(s) referring to the response identified above.
- ☐ A copy of the attorney's Deposit Account Statement in which the item corresponding to the response referred to above is checked.

3. Please proceed with further examination of this application on the basis of:
- ☐ The original papers filed, which have now reached the appropriate area of the PTO.

AND/OR

- ☒ The attached copy of the papers originally filed.

PETITION FEE

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

4. The petition fee (37 CFR 1.17(h)) is paid as follows:

- ☐ Check in the sum of \$130.00.
 - ☒ Charge Account 26-0084 the sum of \$130.00.
- A duplicate of this paper is attached.


REQUEST FOR REFUND OF PETITION FEE

5. ☒ As no defect exists in applicant's previous submission, a refund of the petition fee submitted herewith is respectfully requested.

REQUEST FOR WITHDRAWAL OF ABANDONMENT

6. Acknowledgement of the active status of this application is respectfully requested.

Respectfully submitted,



Edmund J. Sease, Reg. No. 24,741
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No: (515) 288-3667
Fax No: (515) 288-1338
CUSTOMER NO: 22885
Attorneys of Record

- pw -

Auto-Reply Facsimile Transmission



UNITED STATES
PATENT AND
TRADEMARK OFFICE
★★★★

TO: Fax Sender at 5152881338

Fax Information

Date Received:

Total Pages:

4/14/03 2:42:21 PM [Eastern Daylight Time]

8 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page

=====>

04/14/03 MON 12:41 FAX 5152881338 MCKEE VOORHEES & SEASE 0001

MCKEE VOORHEES & SEASE, P.L.C.
~~MCKEE VOORHEES & SEASE, P.L.C.~~

ATTORNEYS AT LAW

801 GRAND AVENUE • SUITE 2200 • DES MOINES, IA 50309-2721
PHONE: 515-284-3667 • FAX: 515-284-1338 • www.jvsa.com

DATE: February 21, 2003

TO: Technology Center 1600 (Art Unit 1654)
Attention Assistant Commissioner for Patents

COMPANY: United States Patent and Trademark Office

FAX: (703) 872-9306

FROM: Edmund J. Sease

NUMBER OF PAGES (Including cover): 8

COMMENTS: Please see the attached regarding the below-captioned application. Thank you.

APPLICANT: BATES, James N.
SERIAL NO: 09/979,710
FILED: June 10, 2001
TITLE: S-METHYLCYSTEINE, S-ETHYLCYSTEINE, AND
RELATED S-ALKYLTHTIOLS AS ANTAGONISTS
TO THE EFFECTS OF S-NITROSOTHTIOLS AND
NITRIC OXIDE

Grp./A.U.: 1654
Examiner: MELLER, Michael V.
Conf. No.: 3776
Docket No.: P04852US0

THE DOCUMENTS ACCOMPANYING THIS FACSIMILE TRANSMISSION COVER SHEET CONTAIN INFORMATION FROM THE
LAW FIRM OF MCKEE, VOORHEES & SEASE WHICH MAY BE CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THE
DOCUMENTS ARE INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE ADDRESSEE IDENTIFIED
ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT OR AN AGENT REPRESENTING HIM, DELIVERING THESE DOCUMENTS
TO THE INTENDED RECIPIENT. YOU ARE HEREBY NOTIFIED THAT ANY REVIEW, DISCLOSURE, COPYING, DISTRIBUTION
OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS TRANSMITTED INFORMATION IS STRICTLY
PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY THIS FIRM SO
THAT WE CAN ARRANGE FOR THE RETURN OF THE ORIGINAL DOCUMENTS TO US. THANK YOU.

Received from 5152881338 - at 04/14/03 2:42:21 PM [Eastern Daylight Time]

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

*** TX REPORT ***

TRANSMISSION OK

TX/RX NO 3438
CONNECTION TEL 17038729306
SUBADDRESS
CONNECTION ID
ST. TIME 04/14 12:41
USAGE T 02'41
PGS. 8
RESULT OK

MCKEE, VOORHEES & SEASE, PLC
WCKEE AOOKHEES & SEVZE, BFC

ATTORNEYS AT LAW

801 GRAND AVENUE • SUITE 3200 • DES MOINES, IA 50309-2721
PHONE: 515-288-3667 • FAX: 515-288-1338 • www.ipmvs.com

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

DATE: February 21, 2003

TO: Technology Center 1600 (Art Unit 1654)
Attention Assistant Commissioner for Patents

COMPANY: United States Patent and Trademark Office

FAX: (703) 872-9306

FROM: Edmund J. Sease

NUMBER OF PAGES (Including cover): 8

COMMENTS: Please see the attached regarding the below-captioned application. Thank you.

APPLICANT: BATES, James N.
SERIAL NO: 09/979,710
FILED: June 10, 2001
TITLE: S-METHYLCYSTEINE, S-ETHYLCYSTEINE, AND
RELATED S-ALKYLTHIOLS AS ANTAGONISTS
TO THE EFFECTS OF S-NITROSO THIOLS AND
NITRIC OXIDE

MCKEE, VOORHEES & SEASE, PLC
WCKEE' AOOK'HEE2 & 2EV2E' b7C

ATTORNEYS AT LAW

801 GRAND AVENUE • SUITE 3200 • DES MOINES, IA 50309-2721
PHONE: 515-288-3667 • FAX: 515-288-1338 • www.ipmvs.com

DATE: February 21, 2003

TO: Technology Center 1600 (Art Unit 1654)
Attention Assistant Commissioner for Patents

COMPANY: United States Patent and Trademark Office

FAX: (703) 872-9306

FROM: Edmund J. Sease

NUMBER OF PAGES (Including cover): 8

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

COMMENTS: Please see the attached regarding the below-captioned application. Thank you.

APPLICANT: BATES, James N.
SERIAL NO: 09/979,710
FILED: June 10, 2001
TITLE: S-METHYLCYSTEINE, S-ETHYLCYSTEINE, AND
RELATED S-ALKYLTHIOLS AS ANTAGONISTS
TO THE EFFECTS OF S-NITROSOTHIOLS AND
NITRIC OXIDE

Grp./A.U.: 1654
Examiner: MELLER, Michael V.
Conf. No.: 3776
Docket No.: P04852US0

THE DOCUMENTS ACCOMPANYING THIS FACSIMILE TRANSMITTAL COVER SHEET CONTAIN INFORMATION FROM THE LAW FIRM OF MCKEE, VOORHEES & SEASE WHICH MAY BE CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THE DOCUMENTS ARE INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE ADDRESSEE IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING THESE DOCUMENTS TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY REVIEW, DISCLOSURE, COPYING, DISTRIBUTION OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS TRANSMITTED INFORMATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY THIS FIRM SO THAT WE CAN ARRANGE FOR THE RETURN OF THE ORIGINAL DOCUMENTS TO US. THANK YOU.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : BATES, JAMES N.
SERIAL NO : 09/879,710
FILED : JUNE 12, 2001
TITLE : S-METHYLCYSTEINE, S-ETHYLCYSTEINE, AND RELATED S-
ALKYLTHIOLS AS ANTAGONISTS TO THE EFFECTS OF S-
NITROSOTHIOLS AND NITRIC OXIDE

Grp./A.U. : 1654
Examiner : MELLER, MICHAEL V.
Conf. No. : 3776
Docket No. : P04852US0

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

Sir:

In response to the Office Action dated January 14, 2003, please amend the above-
identified application as follows:

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☐ deposited with the United States Postal
Service with sufficient postage as first class
mail in an envelope addressed to the
Assistant Commissioner for Patents,
Washington, D.C. 20231.

FACSIMILE

☒ transmitted by facsimile to the
Patent and Trademark Office (703) 872-9306.

Date:

April 14, 2003

EDMUND J. SEASE



In the Claims

Please amend claims 2-4, and 7-8 and add new claim 9 as follows:

2. (Amended)

The method of claim 9 wherein the S-alkylthiol is selected from the group consisting of S-ethylcysteine, S-methylcysteine, S-methylcysteamine, S-ethylcysteamine, S-ethylglutathione, S-methylglutathione, S-methylcoenzyme A, and S-ethylcoenzyme A.

3. (Amended)

The method of claim 9 where in the S-alkylthiol is selected from the group consisting of S-ethyl-L-cysteine, S-methyl-L-cysteine, S-ethylglutathione, S-methylglutathione, S-methylcysteamine, S-ethylcysteamine, S-methylcoenzyme A and S-ethylcoenzyme A.

4. (Amended)

The method of claim 9 wherein the S-alkylthiol is a pharmaceutically acceptable salt form.

7. (Twice Amended)

The method of claim 9 wherein the administration is intravenously.

8. (Twice Amended)

The method of claim 9 wherein the dose ranges from about 100 mg to about 10 g.

9. (New)

A method of treating hypotension comprising:

diagnosing hypotension in a patient;

administering to a patient a therapeutically effective amount of an S-alkylthiol as an antagonist of
S-nitrosothiols; and

observing the effect of the S-alkylthiol on the hypotension.

REMARKS

Amended claim 2 finds support in the specification on p. 3, line 6. New claim 9 finds support in the specification on p. 5, lines 1-17. Treating the disease presupposes diagnosing the condition and necessarily includes observing the effect of the drug on the hypotension.

Claim 1, 3, and 8 were rejected under 35 U.S.C. § 102(b) as anticipated by Meisner. Claim 1 is cancelled. Claims 3 and 8 are amended to depend on new independent claim 9. Meisner does not anticipate claim 9. Specifically, the limitations "diagnosing hypotension in a patient" and "observing the effect of the S-alkylthiol on the hypotension" are not disclosed in Meisner. Meisner makes no connection between S-alkylthiols and hypotension treatment. In fact, Meisner makes no mention of hypotension.

Claims 1-8 were rejected under 35 U.S.C. § 103 as obvious over Meisner taken with Joullie et al. and the Chemical Abstracts Registry file print. Claim 1 is cancelled. Claims 2-4 and 7-8 are amended to depend on new independent claim 9. Meisner, Joullie et al. and the Chemical Abstracts Registry file print do not render claims 2-9 obvious. Specifically, the limitations "diagnosing hypotension in a patient" and "observing the effect of the S-alkylthiol on the hypotension" are not disclosed in Meisner, Joullie et al. and the Chemical Abstracts Registry file print. The references make no connection between S-alkylthiols and hypotension treatment. In fact, the references make no mention of hypotension. Meisner is directed towards wound healing and Joullie et al. is directed towards a laundry list of complaints (col.12, lines 1-15), none of which is hypotension.

Based on the foregoing, Applicants respectfully submit that the pending claims are in condition for allowance at this time, as they are patentably distinguishable over the prior art.

Accordingly, reconsideration of the application and passage to allowance is respectfully submitted.

No fees or extensions of time are believed to be due in connection with this amendment; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account No. 26-0084.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Reconsideration and allowance is respectfully requested.

Respectfully submitted,



EDMUND J. SEASE, Reg. No. 24,741
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

Attorneys of Record

- mlw -

RECEIVED

OCT 2 9 2003

OFFICE OF PETITIONS

AMENDMENT — VERSION WITH MARKINGS
TO SHOW CHANGES MADE

RECEIVED

OCT 29 2003

OFFICE OF PETITIONS

In the Claims

2. (Amended)

The method of claim ~~1~~ 9 wherein the S-alkylthiol is selected from the group consisting of S-ethylcysteine, S-methylcysteine, S-methylcysteamine, S-ethylcysteamine, S-ethylglutathione, S-methylglutathione, S-methylcoenzyme A, and S-ethylcoenzyme A.

3. (Amended)

The method of claim ~~1~~ 9 where in the S-alkylthiol is selected from the group consisting of S-ethyl-L-cysteine, S-methyl-L-cysteine, S-ethylglutathione, S-methylglutathione, S-methylcysteamine, S-ethylcysteamine, S-methylcoenzyme A and S-ethylcoenzyme A.

4. (Amended)

The method of claim ~~1~~ 9 wherein the S-alkylthiol is a pharmaceutically acceptable salt form.

7. (Twice Amended)

The method of claim ~~1~~ 9 wherein the administration is ~~parenterally~~ intravenously.

8. (Twice Amended)

The method of claim ~~1~~ 9 wherein the dose ranges from about ~~1~~ 100 mg to about 10 g.

9. (New)

A method of treating hypotension comprising:

diagnosing hypotension in a patient;

administering to a patient a therapeutically effective amount of an S-alkylthiol as an antagonist

of S-nitrosothiols; and

observing the effect of the S-alkylthiol on the hypotension.